The impact of hemodialysis on the clearance of busulfan was determined in a patient with chronic renal failure undergoing autologous peripheral stem cell transplantation for non-Hodgkin's lymphoma. The extraction ratio for busulfan across the dialyzer was 0.530 ؎ 0.026 at a blood flow of 400 ml/min, which corresponds to a hemodialysis clearance of 2.23 ؎ 0.11 ml/min/kg body weight. Apparent oral clearance of busulfan without hemodialysis was 3.38 ؎ 0.56 ml/min/kg. Thus, a 4 h hemodialysis session enhanced the apparent oral clearance of busulfan by 65%. We conclude that hemodialysis effectively removes busulfan from circulating blood, but a standard hemodialysis period (ie, 4 h) does not significantly alter busulfan exposure. Bone Marrow Transplantation (2000) 25, 201-203. 
High-dose busulfan is a mainstay in the myeloablative conditioning regimens used in preparation for hematopoietic stem cell transplantation. To date, there are few reports regarding the use of busulfan in patients undergoing hemodialysis, as this is an infrequent situation. Busulfan is primarily eliminated by conjugation with glutathione, and less than 2% of an oral dose is eliminated unchanged in the urine. [1] [2] [3] [4] We have found that busulfan conjugation is predominantly catalyzed by glutathione S-transferase (GST) A1-1, 5 a major GST isoform in the liver and kidney. 6 The physico-chemical characteristics of busulfan suggest that it should be effectively removed by hemodialysis.
The purpose of this report is to describe the impact of renal failure and hemodialysis on the apparent clearance (CL/F) of busulfan in a patient undergoing hemodialysis. CL/F is a pharmacokinetic term defined as the ratio of systemic clearance (CL; a specific measure of efficiency of drug elimination) relative to bioavailability (F; the fraction of the dose that transits from the site of administration, in this case the gastro-intestinal tract, to the systemic circulation). These two parameters cannot be evaluated independently with a drug administered only orally.
Case report
A 47-year-old male was originally diagnosed with small cleaved, poorly differentiated lymphocytic lymphoma 5 years prior to peripheral blood stem cell transplantation. He presented with renal failure associated with massive retroperitoneal lymphadenopathy and was diagnosed as having non-Hodgkin's lymphoma. Chronic hypertension and ureteral obstruction led to end stage renal disease requiring initiation of hemodialysis in April 1993. The patient relapsed after initial chemotherapy and subsequently developed diffuse large cell lymphoma 9 months prior to peripheral blood stem cell transplantation. Autologous stem cell transplantation was chosen as a treatment option after failure to find an HLA-matched relative.
Partial remission was induced with three cycles of cyclophosphamide, etoposide and procarbazine 4 months prior to stem cell transplantation. Mobilization was initiated 6 weeks later with cyclophosphamide, etoposide, dexamethasone and G-CSF, and two collections of 490 × 10 6
CD34
+ cells were obtained by leukapheresis. Starting on 9 May 1994, he received myeloablation therapy at St Joseph Medical Center in Tacoma, WA, which consisted of five test doses and 14 therapeutic doses of busulfan given every 6 h over 5 days, followed by two daily infusions of cyclophosphamide (100 and 50 mg/kg). The patient received 0.17 mg/kg oral busulfan every 6 h for doses 1-5 to determine the effect of hemodialysis for the purpose of planning therapy, followed by 0.60-1.0 mg/kg oral busulfan every 6 h for 14 additional doses over 4 days (19 total doses). Busulfan doses 1, 5, 9 and 13 were administered at the start of a 4-h hemodialysis session.
Samples were collected from arterial blood entering and venous blood leaving the dialyzer 0, 30, 60, 90, 120, 180 and 240 min after the administration of busulfan, and venous samples were collected 300 and 360 min after the administration of busulfan. For busulfan doses 4, 8, 12 and 18, venous blood samples were drawn from a Hickman catheter at times 0, 60, 120, 240, 300 and 360 min after busulfan administration. Plasma was separated by centrifugation, and busulfan concentrations were determined by gas chromatography with mass selective detection as previously described. 7 A Drake Willock System 1000 (Althin Medical, Portland, OR, USA) was used for hemodialysis with a Fresenius Hemoflow F8 Hollow Fiber Dialyzer (Fresenius USA, Walnut Creek, CA, USA) with a blood flow (Q B ) of 400 ml/min and dialysate flow of 500 ml/min. A left arm polytetrafluoroethylene graft was used for dialysis access. The dialyzer membrane was reused after processing with an automated renalin system (Minntech Corporation, Minneapolis, MN, USA).
Busulfan CL/F was calculated from the dose of busulfan and the trapezoidal area under the concentration-time curve for venous plasma concentrations (AUC) after doses 4, 8, 12 and 18. (We have found that the blood to plasma concentration ratio for busulfan is 0.99. Thus, clearance estimated from plasma busulfan concentrations would be equivalent to the clearance estimated from blood busulfan concentrations). Each of these doses was administered at least 14 h after the end of the previous hemodialysis session. The extraction ratio for busulfan across the Fresenius F8 membrane during dialysis was obtained by subtracting the venous AUC from the arterial AUC and dividing by the arterial AUC. 8 Busulfan clearance by hemodialysis (CL HD ) was calculated as the product of extraction ratio and Q B .
The amount of busulfan eliminated in the dialysate was estimated by determining busulfan AUC in dialysate over 4 h and multiplying that by the dialysate flow rate and adding the product of the volume of dialysate at the end of the dialysis period (310 ml) and the busulfan concentration in dialysate at that time.
Owing to the patient's end stage renal disease and chronic hemodialysis requirements, busulfan levels were measured frequently and the necessary dose adjustments were made in order to achieve a target steady-state concentration of 500-600 ng/ml. For doses 1-5, a 0.17 mg/kg busulfan test dose was administered to characterize the effect of hemodialysis on the disposition of busulfan. The hemodialysis extraction ratio and CL HD (mean ± s.d.) for busulfan were 0.530 ± 0.026 and 2.23 ± 0.11 ml/min/kg body weight (Table 1 ). Figure 1 shows representative busulfan concentration-time data for venous blood samples obtained between doses 8 and 9, and concentration-time data for arterial blood entering and venous blood leaving the dialyzer between doses 9 and 10. The shape of the venous plasma concentration-time curve during dialysis is similar to that observed in its absence, except for the rebound of concentration seen at the end of dialysis. After doses 1, 5, 9 and 13, venous busulfan concentrations increased 99.2 ± 41.2% 60 min after the end of dialysis. Busulfan CL/F was 3.38 ± 0.56 ml/min/kg without concurrent hemodialysis ( Table 1 ). The fraction of the amount of busulfan eliminated during hemodialysis that was recovered in the dialysate was 0.743 and 0.688 after doses 1 and 5. The overall average steady-state busulfan concentration was 523 ng/ml (which corresponds to an AUC of 765 m × min), and 665 ng/ml (or an AUC of 973 m × min) excluding test doses 1-5.
The patient achieved the myelosuppression expected with the conditioning regimen. By day 13 post transplant, he had an ANC Ͼ 1500 cells/l and was platelet transfusion independent. He achieved a complete remission and remained disease-free for 3 years. He was last examined approximately 3 months before his death, which was caused by complications from end stage renal disease. At the time of death, there was no evidence of lymphoma.
The data in a single patient indicate that busulfan is efficiently eliminated by hemodialysis. We found that the hemodialysis clearance of busulfan was comparable to the patient's CL/F without hemodialysis (2.33 ± 0.11 vs 3.38 ± 0.56 ml/min/kg). Hemodialysis enhanced the elimin-ation of busulfan by 65%. Furthermore, 53% of busulfan in blood entering the dialyzer was extracted on a single pass across the Fresenius F8 dialyzer membrane.
The intermediate extraction efficiency for busulfan crossing the dialyzer membrane is reasonable given the physicochemical characteristics of busulfan. The factors that favor extraction and hemodialysis clearance of busulfan include: (1) low molecular weight (246 Da); (2) low plasma protein binding (7.4%); 2 and (3) blood/plasma partition ratio close to unity (0.99; data not shown).
Over 70% of the amount of busulfan eliminated by hemodialysis was accounted for in the dialysate. Presumably, the unrecovered fraction was irreversibly bound to the membrane filter, consistent with the electrophilicity of this alkylator. 9 In patients with normal renal function, we have found the mean busulfan CL/F is 2.82 ± 0.65 ml/min/kg body weight (n = 279). 10 The CL/F of busulfan in this patient with chronic renal failure was very close to the mean value we have observed, indicating that the kidneys do not play a major role in the metabolic elimination of busulfan. In fact, the total organ GSTA1 content of the kidneys is much lower than that of the liver (1500 vs 140 mg GSTA1 per g whole organ, liver vs kidneys, respectively, based on liver and kidney weights of 1500 and 300 g and GSTA1 monomer contents of 12.8 Ϯ 5.5 and 5.8 Ϯ 4.3 mg/g cytosolic protein). 6 The liver is the major organ responsible for the systemic elimination of busulfan.
An estimate of mean daily CL/F can be obtained by using the mean CL/F during non-dialysis periods and CL/F contributed by hemodialysis: daily CL/F = ͩ (240 min × CL HD ) + (1440 min × CL/F) 1440 min ͪ Thus, a mean daily CL/F value of 3.60 ml/min/kg is obtained, which is 11% greater than the mean daily CL/F without hemodialysis. Therefore, a 4 h daily hemodialysis had a minor impact on the mean daily CL/F even though busulfan is efficiently cleared by dialysis. Since CL/F is increased by 65% during the hemodialysis session, longer sessions can be expected to have a greater impact. Thus, hemo-dialysis could be used to remove an overdose, assuming the error was detected before the drug had been removed by normal physiologic processes. We have not attempted to directly determine the total CL/F (CL HD + CL/F) during dosing intervals where hemodialysis was undertaken. The periodic addition of CL HD to CL/F violates the steady-state assumption preventing the use of the AUC over the dosing interval to determine the total CL/F.
We conclude that while busulfan is efficiently removed from the body by hemodialysis, a 4 h hemodialysis session modestly increases the daily busulfan CL/F. The data from Bone Marrow Transplantation this single subject indicate that total daily busulfan CL/F increased 11% with a 4 h period of dialysis. Thus, if it were desired to maintain levels of busulfan in this individual as they would have been in the absence of dialysis, the dose could be increased by 11% to compensate for the effect of dialysis on total daily CL/F (to 1.11 mg/kg from 1 mg/kg) or the dose ingested at the time of dialysis could be (approximately) doubled to account for the enhanced clearance during dialysis. The timing of dialysis in relation to the administration of busulfan is not critical.
Given the high degree of variability in busulfan CL/F in patients undergoing hematopoietic stem cell transplantation and the relatively narrow range of therapeutic busulfan concentrations, plasma busulfan concentration monitoring is warranted in patients undergoing hemodialysis. 7, 11 
